Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy
- 30 April 2011
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Immunology
- Vol. 23 (2), 299-305
- https://doi.org/10.1016/j.coi.2010.12.012
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17–secreting T cellsBlood, 2011
- Of Mice, Not Men: No Evidence for Graft-versus-Host Disease in Humans Receiving T-Cell Receptor–Transduced Autologous T CellsMolecular Therapy, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- A Transposon and Transposase System for Human ApplicationMolecular Therapy, 2010
- A Distinct Subset of Self-Renewing Human Memory CD8+ T Cells Survives Cytotoxic ChemotherapyImmunity, 2009
- Preclinical development of T cell receptor gene therapyCurrent Opinion in Immunology, 2009
- Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expressionCancer Immunology, Immunotherapy, 2008
- Peripheral CD8+ T Cell Tolerance to Self-Proteins Is Regulated Proximally at the T Cell ReceptorImmunity, 2008
- Heterogeneity and Cell-Fate Decisions in Effector and Memory CD8+ T Cell Differentiation during Viral InfectionImmunity, 2007